ArticleQuantitative imaging in medicine and surgery2018
Article in Quantitative imaging in medicine and surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.EJNMMI research · 2026Review
- Cell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinoma.JHEP reports : innovation in hepatology · 2026Article
- A Look Behind the Paper: Glypican-3-targeted US Molecular Imaging of Hepatocellular Carcinoma.Radiology. Imaging cancer · 2026Article
- Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.Journal of nanobiotechnology · 2024Review
- The Application of Aptamer and Research Progress in Liver Disease.Molecular biotechnology · 2024Review
- Molecular design and synthesis of methoxy-substitued spiropyrans with photomodulated NIR-fluorescence.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Article
- Review
- A highly sensitive strategy for glypican-3 detection based on aptamer/gold carbon dots/magnetic graphene oxide nanosheets as fluorescent biosensor.Analytical and bioanalytical chemistry · 2022Article
- Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment.View (Beijing, China) · 2022Article
- Fast and Durable Intraoperative Near-infrared Imaging of Ovarian Cancer Using Ultrabright Squaraine Fluorophores.Angewandte Chemie (International ed. in English) · 2022Article
- Aptamers used for molecular imaging and theranostics - recent developments.Theranostics · 2022Review
- Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.American journal of nuclear medicine and molecular imaging · 2022Review
- Article
- Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review.Medicina (Kaunas, Lithuania) · 2021Review
- Super-stable homogeneous iodinated formulation technology for improving the therapeutic effect of patients with advanced hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2020Article
- Machine Learning Aided Photonic Diagnostic System for Minimally Invasive Optically Guided Surgery in the Hepatoduodenal Area.Diagnostics (Basel, Switzerland) · 2020Article
- Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer.Pharmaceutics · 2020Article
- Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.Molecular imaging and biology · 2020Article
- Glypican-3 electrochemical aptamer nanobiosensor based on hemin/graphene nanohybrids peroxidase-like catalytic silver deposition.Mikrochimica acta · 2020Article
- Intravital assessment of angioarchitecture in rat hepatocellular nodules usingQuantitative imaging in medicine and surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlypican-3 (GPC3) is highly expressed in most of the hepatocellular carcinomas (HCCs), even in small HCCs. It may be used as a potential biomarker for early detection of HCC. The aptamer is a promising targeting agent with unique advantages over antibody. This study was to introduce a novel GPC3 specific aptamer (AP613-1), to verify its specific binding property
methodsAP613-1 was generated from the systematic evolution of ligands by exponential enrichment. Flow cytometry and aptamer-based immunofluorescence imaging were performed to verify the binding affinity of AP613-1 to GPC3
resultsAP613-1 could specifically bind to GPC3
conclusionsAP613-1 displays a specific binding affinity to GPC3 positive HCC. Fluorescently labeled AP613-1 could be used as an imaging probe to subcutaneous HCC in xenograft models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.